# Systemic Therapy Update



November 2013 Volume 16, Number 11, Supplement 1

## For Health Professionals Who Care For Cancer Patients

### **SUPPLEMENT**

## HIGHLIGHTS OF CHANGES IN PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS

The Provincial Systemic Therapy Program has revised the following program effective 15 November 2013:

### **Genitourinary:**

The Genitourinary Tumour Group has expanded the eligibility criteria for the use of abiraterone with prednisone to patients with "asymptomatic" metastatic castration resistant prostate cancer (mCRPC) who have not received prior chemotherapy (UGUPABI). This program was previously approved only for patients with "symptomatic" disease who have received prior docetaxel-containing chemotherapy or who were ineligible for chemotherapy. Approval of the new program was based on a phase III randomized controlled trial that evaluated abiraterone with prednisone versus prednisone alone in chemotherapy-naïve patients with asymptomatic or mildly symptomatic (ECOG 0 to 1) mCRPC. [Ryan et al. NEJM 2013;368:138-148] Abiraterone was associated with a significant increase in radiologic progression free survival (16.5 mo vs. 8.3 mos, HR 0.53 [95% CI 0.45-0.62]), and a trend towards improved overall survival (not yet reached vs. 27.2 mo, HR 0.75 [95% CI 0.61-0.93). Abiraterone with prednisone was overall well tolerated, and significantly delayed the median time to the initiation of chemotherapy (25.2 mo vs. 16.8 mo, HR 0.58 [95% CI 0.49-0.69]).

Website Resources and Contact Information			
WEBSITE RESOURCES	www.bccancer.bc.ca		
Systemic Therapy Update	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/stupdate		
Reimbursement & Forms: Benefit Drug List, Class II, Compassionate Access Program	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Forms		
Cancer Drug Manual	www.bccancer.bc.ca/cdm		
Cancer Management Guidelines	www.bccancer.bc.ca/CaMgmtGuidelines		
Cancer Chemotherapy Protocols, Pre-printed Orders, Protocol Patient Handouts	www.bccancer.bc.ca/ChemoProtocols		
Systemic Therapy Program Policies	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Policies		
CON Pharmacy Educators	http://www.bccancer.bc.ca/HPI/Pharmacy/ContactUs.htm		

CONTACT INFORMATION	PHONE	FAX	EMAIL
Systemic Therapy Update Editor	604.877.6000 x 673028		sally.waignein@bccancer.bc.ca
Provincial Systemic Therapy Program	250.712.3900 x 686620		mberk@bccancer.bc.ca
To update the contact information of any CON sites, please contact:			bulletin@bccancer.bc.ca
Oncology Drug Information	604.877.6275		druginfo@bccancer.bc.ca
Education Resource Nurse	604.877.6000 x 672638		nursinged@bccancer.bc.ca
Library/Cancer Information	604.675.8003 Toll Free 888.675.8001 x 8003		requests@bccancer.bc.ca
Pharmacy Professional Practice	250. 519.5574		jkippen@bccancer.bc.ca
Nursing Professional Practice	604.877.6000 x 672623		ilundie@bccancer.bc.ca
OSCAR	888.355.0355	604.708.2051	oscar@bccancer.bc.ca
Compassionate Access Program (CAP)	604.877.6277	604.708.2026	<pre>cap_bcca@bccancer.bc.ca</pre>
Pharmacy Chemotherapy Certification	250.712.3900 x 686741		rxchemocert@bccancer.bc.ca
BCCA-Abbotsford Centre	604.851.4710 Toll Free 877.547.3777		
BCCA-Centre for the North	250.645.7300 Toll Free 888.775.7300		
BCCA-Fraser Valley Centre	604.930.2098 Toll Free 800.523.2885		
BCCA-Sindi Ahluwalia Hawkins Centre for the Southern Interior	250.712.3900 Toll Free 888.563.7773		
BCCA-Vancouver Centre	604.877.6000 Toll Free 800.663.3333		
BCCA-Vancouver Island Centre	250.519.5500 Toll Free 800.670.3322		

# **EDITORIAL REVIEW BOARD**

Sally Waignein, PharmD (Editor) Mário de Lemos, PharmD, MSc (Oncol) Caroline Lohrisch, MD Beth Morrison, MLS Susan Walisser, BSc (Pharm)